Radiogenomics and genomics-guided radiotherapy, including tumor radiosensitivity and dose personalization

From November 2025

Postmastectomy chest-wall irradiation may be omitted in intermediate-risk breast cancer without compromising survival, ref: Kunkler doi.org/10.1056/NEJMoa2412225/
Preoperative pembrolizumab combined with chemoradiotherapy shows promise in esophageal squamous cell carcinoma, ref: Li doi.org/10.1038/s41392-025-02477-4/
KAT2A-driven succinylation enhances radioresistance in hepatocellular carcinoma, ref: Wu doi.org/10.1038/s41392-025-02458-7/
TRIM25 ablation enhances immunotherapy efficacy by regulating VISTA, ref: Sun doi.org/10.1038/s41422-025-01186-5/
Alternate-day fasting impairs AR translation in prostate cancer, revealing metabolic vulnerabilities, ref: Anzules doi.org/10.1158/0008-5472.CAN-25-3234/
Lipid droplet-targeted therapies can enhance radiosensitivity in cancer treatment, ref: Xu doi.org/10.1002/adhm.202504496/
The optimal duration of androgen deprivation therapy significantly impacts prostate cancer management, ref: Zaorsky doi.org/10.1001/jamaoncol.2025.4800/
CNOT7 mediates radiation resistance in colorectal cancer through enhanced DNA repair, ref: Li doi.org/10.1038/s41419-025-08160-4/

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec